Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center

Alicia McGhie; Jenessa Lee; Alessandra Ferrajoli; Adam J. DiPippo

doi:10.1080/10428194.2023.2185089

Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center

Alicia McGhie, Jenessa Lee, Alessandra Ferrajoli, Adam J. DiPippo

Leukemia

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1050-1053
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	64
Issue number	5
DOIs	https://doi.org/10.1080/10428194.2023.2185089
State	Published - 2023

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2023.2185089

Cite this

@article{192e9c4220194bbea891ed9b9316ae8e,

title = "Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center",

author = "Alicia McGhie and Jenessa Lee and Alessandra Ferrajoli and DiPippo, {Adam J.}",

note = "Funding Information: A.F.: research funds: Astra-Zeneca and Beigene, advisory board: Janssen, Astra-Zeneca. Chun Feng, M.A., Certified ASQ Six Sigma Black Belt, Sr. Informatics Analyst–Department of Pharmacy–Quality and Regulatory, Division of Pharmacy, University of Texas M.D. Anderson Cancer Center.",

year = "2023",

doi = "10.1080/10428194.2023.2185089",

language = "English (US)",

volume = "64",

pages = "1050--1053",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Tolerability of acalabrutinib in patients with CLL

T2 - experience of a tertiary cancer care center

AU - McGhie, Alicia

AU - Lee, Jenessa

AU - Ferrajoli, Alessandra

AU - DiPippo, Adam J.

N1 - Funding Information: A.F.: research funds: Astra-Zeneca and Beigene, advisory board: Janssen, Astra-Zeneca. Chun Feng, M.A., Certified ASQ Six Sigma Black Belt, Sr. Informatics Analyst–Department of Pharmacy–Quality and Regulatory, Division of Pharmacy, University of Texas M.D. Anderson Cancer Center.

PY - 2023

Y1 - 2023

UR - http://www.scopus.com/inward/record.url?scp=85150503184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150503184&partnerID=8YFLogxK

U2 - 10.1080/10428194.2023.2185089

DO - 10.1080/10428194.2023.2185089

M3 - Letter

C2 - 36891585

AN - SCOPUS:85150503184

SN - 1042-8194

VL - 64

SP - 1050

EP - 1053

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5

ER -

Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this